SEC Form 4 · accession 0001193125-26-338665
KESTRA MEDICAL TECHNOLOGIES, LTD. · KMTS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vaseem Mahboob
Officer — Chief Financial Officer
Period of report
Aug 4, 2026
Accepted (ET)
Aug 6, 2026 · 7:04 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001877184
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF2 | Aug 4, 2026 | S | 3,080 | $24.057 | D | 90,811 | D | |
| Common SharesF4 | Aug 4, 2026 | S | 3,915 | $25.1696 | D | 86,896 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
- F2The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.9030 to $24.4200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
- F3The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2025.
- F4The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.0000 to $25.3800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.